FDA delays decision on Rocket gene therapy
14 Feb 2024
Clinical ResultPriority ReviewPhase 2Gene TherapyImmunotherapy
The U.S. FDA has extended the priority review period by three months for Rocket Pharmaceuticals' autologous gene therapy for a rare pediatric immunodeficiency disorder.
The investigational therapy, branded Kresladi (marnetegragene autotemcel), originally had a PDUFA date of March 31 for leukocyte adhesion deficiency-I (LAD-I). The FDA pushed the date to June 30, to allow additional time to review clarifying chemistry, manufacturing and controls information submitted by Rocket in response to the agency's information requests. According to Rocket, the FDA confirmed no advisory committee meeting will be needed.
LAD-1 is caused by mutations in the ITGB2 gene encoding for the beta-2 integrin component CD18, a key protein needed to combat infections. Rocket's Kresladi contains autologous hematopoietic stem cells that have been genetically modified with a lentiviral vector to deliver a functional copy of the ITGB2 gene, which encodes for the beta-2 integrin component CD18.
The NJ-based biotech is hopeful that the therapy has the potential to change the treatment paradigm for patients living with severe LAD-I — one of the most aggressive and highly fatal immunodeficiencies ever characterized. Without a successful bone marrow transplant, mortality in patients with severe LAD-I is 60-75% prior to the age of 2 and survival beyond the age of 5 is uncommon, according to Rocket.
Back in 2022, Rocket revealed promising phase 2 trial results: 3-24 months after Kresladi (then RP-L201) infusion, all nine trial patients sustained stable CD18 expression with no therapy-related serious adverse events. Furthermore, among all participants, the overall survival at one year was 100% — and patients are reporting a statistically significant reduction in all hospitalizations.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.